nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.0627	0.0911	CbGbCtD
Methotrimeprazine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0563	0.0818	CbGbCtD
Methotrimeprazine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0529	0.0769	CbGbCtD
Methotrimeprazine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0529	0.0769	CbGbCtD
Methotrimeprazine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0478	0.0695	CbGbCtD
Methotrimeprazine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0464	0.0674	CbGbCtD
Methotrimeprazine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0436	0.0633	CbGbCtD
Methotrimeprazine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0436	0.0633	CbGbCtD
Methotrimeprazine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0401	0.0583	CbGbCtD
Methotrimeprazine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0394	0.0573	CbGbCtD
Methotrimeprazine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0394	0.0573	CbGbCtD
Methotrimeprazine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0363	0.0527	CbGbCtD
Methotrimeprazine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.034	0.0494	CbGbCtD
Methotrimeprazine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.033	0.048	CbGbCtD
Methotrimeprazine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0299	0.0434	CbGbCtD
Methotrimeprazine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0299	0.0434	CbGbCtD
Methotrimeprazine—Liver injury—Didanosine—acquired immunodeficiency syndrome	0.00512	0.0419	CcSEcCtD
Methotrimeprazine—Drug interaction—Didanosine—acquired immunodeficiency syndrome	0.00465	0.038	CcSEcCtD
Methotrimeprazine—Liver injury—Nevirapine—acquired immunodeficiency syndrome	0.00461	0.0377	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Didanosine—acquired immunodeficiency syndrome	0.00431	0.0353	CcSEcCtD
Methotrimeprazine—DRD1—nerve—acquired immunodeficiency syndrome	0.00426	0.0515	CbGeAlD
Methotrimeprazine—Drug interaction—Nevirapine—acquired immunodeficiency syndrome	0.00418	0.0342	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Nevirapine—acquired immunodeficiency syndrome	0.00388	0.0317	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Stavudine—acquired immunodeficiency syndrome	0.00374	0.0306	CcSEcCtD
Methotrimeprazine—Drug interaction—Zidovudine—acquired immunodeficiency syndrome	0.00351	0.0287	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Zidovudine—acquired immunodeficiency syndrome	0.00325	0.0266	CcSEcCtD
Methotrimeprazine—Liver injury—Ritonavir—acquired immunodeficiency syndrome	0.00301	0.0246	CcSEcCtD
Methotrimeprazine—Drug interaction—Delavirdine—acquired immunodeficiency syndrome	0.00295	0.0241	CcSEcCtD
Methotrimeprazine—Drug interaction—Ritonavir—acquired immunodeficiency syndrome	0.00273	0.0223	CcSEcCtD
Methotrimeprazine—Drug interaction—Saquinavir—acquired immunodeficiency syndrome	0.00262	0.0215	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Ritonavir—acquired immunodeficiency syndrome	0.00253	0.0207	CcSEcCtD
Methotrimeprazine—DRD2—nerve—acquired immunodeficiency syndrome	0.00252	0.0304	CbGeAlD
Methotrimeprazine—Drug interaction—Lamivudine—acquired immunodeficiency syndrome	0.0025	0.0205	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Didanosine—acquired immunodeficiency syndrome	0.00225	0.0184	CcSEcCtD
Methotrimeprazine—Jaundice—Nevirapine—acquired immunodeficiency syndrome	0.00211	0.0173	CcSEcCtD
Methotrimeprazine—Jaundice—Nelfinavir—acquired immunodeficiency syndrome	0.00205	0.0168	CcSEcCtD
Methotrimeprazine—Jaundice—Stavudine—acquired immunodeficiency syndrome	0.00204	0.0167	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Nevirapine—acquired immunodeficiency syndrome	0.00202	0.0166	CcSEcCtD
Methotrimeprazine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00182	0.022	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00181	0.0148	CcSEcCtD
Methotrimeprazine—Jaundice—Zidovudine—acquired immunodeficiency syndrome	0.00177	0.0145	CcSEcCtD
Methotrimeprazine—Urinary retention—Ritonavir—acquired immunodeficiency syndrome	0.00175	0.0143	CcSEcCtD
Methotrimeprazine—Weight increased—Indinavir—acquired immunodeficiency syndrome	0.00173	0.0141	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Zidovudine—acquired immunodeficiency syndrome	0.0017	0.0139	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00168	0.0137	CcSEcCtD
Methotrimeprazine—HTR2A—nerve—acquired immunodeficiency syndrome	0.00166	0.0201	CbGeAlD
Methotrimeprazine—Jaundice—Indinavir—acquired immunodeficiency syndrome	0.00165	0.0135	CcSEcCtD
Methotrimeprazine—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.00164	0.0198	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Efavirenz—acquired immunodeficiency syndrome	0.00164	0.0134	CcSEcCtD
Methotrimeprazine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00161	0.0194	CbGeAlD
Methotrimeprazine—Drowsiness—Efavirenz—acquired immunodeficiency syndrome	0.0016	0.0131	CcSEcCtD
Methotrimeprazine—Weight increased—Delavirdine—acquired immunodeficiency syndrome	0.00156	0.0128	CcSEcCtD
Methotrimeprazine—Jaundice—Efavirenz—acquired immunodeficiency syndrome	0.00156	0.0128	CcSEcCtD
Methotrimeprazine—Jaundice—Delavirdine—acquired immunodeficiency syndrome	0.00149	0.0122	CcSEcCtD
Methotrimeprazine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00148	0.0178	CbGeAlD
Methotrimeprazine—DRD4—brain—acquired immunodeficiency syndrome	0.00146	0.0176	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Ritonavir—acquired immunodeficiency syndrome	0.00145	0.0119	CcSEcCtD
Methotrimeprazine—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.00144	0.0175	CbGeAlD
Methotrimeprazine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.00144	0.0174	CbGeAlD
Methotrimeprazine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00141	0.0171	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Saquinavir—acquired immunodeficiency syndrome	0.00139	0.0114	CcSEcCtD
Methotrimeprazine—Weight increased—Saquinavir—acquired immunodeficiency syndrome	0.00139	0.0114	CcSEcCtD
Methotrimeprazine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.00139	0.0168	CbGeAlD
Methotrimeprazine—Jaundice—Ritonavir—acquired immunodeficiency syndrome	0.00138	0.0113	CcSEcCtD
Methotrimeprazine—DRD3—nervous system—acquired immunodeficiency syndrome	0.00134	0.0162	CbGeAlD
Methotrimeprazine—Jaundice—Saquinavir—acquired immunodeficiency syndrome	0.00133	0.0109	CcSEcCtD
Methotrimeprazine—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00129	0.0156	CbGeAlD
Methotrimeprazine—Jaundice—Lamivudine—acquired immunodeficiency syndrome	0.00127	0.0104	CcSEcCtD
Methotrimeprazine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00126	0.0152	CbGeAlD
Methotrimeprazine—DRD5—nervous system—acquired immunodeficiency syndrome	0.00125	0.0152	CbGeAlD
Methotrimeprazine—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.00123	0.0101	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Lamivudine—acquired immunodeficiency syndrome	0.00121	0.00992	CcSEcCtD
Methotrimeprazine—DRD5—central nervous system—acquired immunodeficiency syndrome	0.00121	0.0146	CbGeAlD
Methotrimeprazine—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.00119	0.00975	CcSEcCtD
Methotrimeprazine—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.00119	0.00972	CcSEcCtD
Methotrimeprazine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00114	0.0138	CbGeAlD
Methotrimeprazine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00114	0.00935	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00113	0.00927	CcSEcCtD
Methotrimeprazine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.00113	0.0136	CbGeAlD
Methotrimeprazine—CHRM4—brain—acquired immunodeficiency syndrome	0.0011	0.0133	CbGeAlD
Methotrimeprazine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.00108	0.0131	CbGeAlD
Methotrimeprazine—DRD2—retina—acquired immunodeficiency syndrome	0.00104	0.0126	CbGeAlD
Methotrimeprazine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00103	0.00844	CcSEcCtD
Methotrimeprazine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.00103	0.0124	CbGeAlD
Methotrimeprazine—DRD3—brain—acquired immunodeficiency syndrome	0.00102	0.0124	CbGeAlD
Methotrimeprazine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00102	0.00834	CcSEcCtD
Methotrimeprazine—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.00101	0.0122	CbGeAlD
Methotrimeprazine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000995	0.00815	CcSEcCtD
Methotrimeprazine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000992	0.00812	CcSEcCtD
Methotrimeprazine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00099	0.012	CbGeAlD
Methotrimeprazine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000987	0.00808	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000984	0.00805	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000969	0.00793	CcSEcCtD
Methotrimeprazine—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.000968	0.0117	CbGeAlD
Methotrimeprazine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000959	0.00785	CcSEcCtD
Methotrimeprazine—DRD5—brain—acquired immunodeficiency syndrome	0.000959	0.0116	CbGeAlD
Methotrimeprazine—DRD1—nervous system—acquired immunodeficiency syndrome	0.000958	0.0116	CbGeAlD
Methotrimeprazine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000952	0.00779	CcSEcCtD
Methotrimeprazine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000923	0.00755	CcSEcCtD
Methotrimeprazine—DRD1—central nervous system—acquired immunodeficiency syndrome	0.000923	0.0112	CbGeAlD
Methotrimeprazine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000906	0.00742	CcSEcCtD
Methotrimeprazine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000884	0.0107	CbGeAlD
Methotrimeprazine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000881	0.00721	CcSEcCtD
Methotrimeprazine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000872	0.00714	CcSEcCtD
Methotrimeprazine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000867	0.0071	CcSEcCtD
Methotrimeprazine—CHRM5—brain—acquired immunodeficiency syndrome	0.00086	0.0104	CbGeAlD
Methotrimeprazine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000834	0.00683	CcSEcCtD
Methotrimeprazine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000814	0.00983	CbGeAlD
Methotrimeprazine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000802	0.00657	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000795	0.00651	CcSEcCtD
Methotrimeprazine—ADRA1B—brain—acquired immunodeficiency syndrome	0.000786	0.0095	CbGeAlD
Methotrimeprazine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000772	0.00933	CbGeAlD
Methotrimeprazine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000772	0.00632	CcSEcCtD
Methotrimeprazine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000771	0.00632	CcSEcCtD
Methotrimeprazine—ADRA1D—brain—acquired immunodeficiency syndrome	0.000769	0.00929	CbGeAlD
Methotrimeprazine—CHRM1—lung—acquired immunodeficiency syndrome	0.000759	0.00918	CbGeAlD
Methotrimeprazine—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000756	0.00914	CbGeAlD
Methotrimeprazine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000751	0.00615	CcSEcCtD
Methotrimeprazine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000744	0.009	CbGeAlD
Methotrimeprazine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000744	0.00899	CbGeAlD
Methotrimeprazine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000743	0.00608	CcSEcCtD
Methotrimeprazine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000736	0.00603	CcSEcCtD
Methotrimeprazine—DRD1—brain—acquired immunodeficiency syndrome	0.000733	0.00885	CbGeAlD
Methotrimeprazine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000719	0.00588	CcSEcCtD
Methotrimeprazine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000717	0.00866	CbGeAlD
Methotrimeprazine—ADRA1A—blood—acquired immunodeficiency syndrome	0.000712	0.0086	CbGeAlD
Methotrimeprazine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000708	0.0058	CcSEcCtD
Methotrimeprazine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000703	0.0085	CbGeAlD
Methotrimeprazine—HTR2A—retina—acquired immunodeficiency syndrome	0.000688	0.00831	CbGeAlD
Methotrimeprazine—ADRA2C—blood—acquired immunodeficiency syndrome	0.000678	0.00819	CbGeAlD
Methotrimeprazine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000677	0.00818	CbGeAlD
Methotrimeprazine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000665	0.00544	CcSEcCtD
Methotrimeprazine—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000653	0.00789	CbGeAlD
Methotrimeprazine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00064	0.00524	CcSEcCtD
Methotrimeprazine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000629	0.0076	CbGeAlD
Methotrimeprazine—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000629	0.0076	CbGeAlD
Methotrimeprazine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000618	0.00746	CbGeAlD
Methotrimeprazine—DRD2—lung—acquired immunodeficiency syndrome	0.000611	0.00739	CbGeAlD
Methotrimeprazine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00061	0.005	CcSEcCtD
Methotrimeprazine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000606	0.00732	CbGeAlD
Methotrimeprazine—ADRA2C—lung—acquired immunodeficiency syndrome	0.000594	0.00718	CbGeAlD
Methotrimeprazine—CHRM2—brain—acquired immunodeficiency syndrome	0.00059	0.00713	CbGeAlD
Methotrimeprazine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000588	0.00711	CbGeAlD
Methotrimeprazine—HRH1—digestive system—acquired immunodeficiency syndrome	0.000578	0.00699	CbGeAlD
Methotrimeprazine—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000578	0.00698	CbGeAlD
Methotrimeprazine—HTR2C—brain—acquired immunodeficiency syndrome	0.000569	0.00688	CbGeAlD
Methotrimeprazine—DRD2—nervous system—acquired immunodeficiency syndrome	0.000566	0.00684	CbGeAlD
Methotrimeprazine—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000562	0.0068	CbGeAlD
Methotrimeprazine—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000556	0.00672	CbGeAlD
Methotrimeprazine—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.000556	0.00671	CbGeAlD
Methotrimeprazine—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.00055	0.00665	CbGeAlD
Methotrimeprazine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000545	0.00659	CbGeAlD
Methotrimeprazine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000541	0.00654	CbGeAlD
Methotrimeprazine—CHRM1—brain—acquired immunodeficiency syndrome	0.000537	0.00649	CbGeAlD
Methotrimeprazine—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.00053	0.0064	CbGeAlD
Methotrimeprazine—CYP2E1—blood—acquired immunodeficiency syndrome	0.000529	0.0064	CbGeAlD
Methotrimeprazine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000521	0.0063	CbGeAlD
Methotrimeprazine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000516	0.00623	CbGeAlD
Methotrimeprazine—HRH1—vagina—acquired immunodeficiency syndrome	0.000511	0.00617	CbGeAlD
Methotrimeprazine—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.00051	0.00616	CbGeAlD
Methotrimeprazine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000502	0.00606	CbGeAlD
Methotrimeprazine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000483	0.00584	CbGeAlD
Methotrimeprazine—HRH1—lung—acquired immunodeficiency syndrome	0.000483	0.00584	CbGeAlD
Methotrimeprazine—CHRM3—brain—acquired immunodeficiency syndrome	0.000481	0.00581	CbGeAlD
Methotrimeprazine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000474	0.00573	CbGeAlD
Methotrimeprazine—CYP2E1—lung—acquired immunodeficiency syndrome	0.000464	0.00561	CbGeAlD
Methotrimeprazine—HTR2A—blood—acquired immunodeficiency syndrome	0.00046	0.00556	CbGeAlD
Methotrimeprazine—HRH1—nervous system—acquired immunodeficiency syndrome	0.000447	0.0054	CbGeAlD
Methotrimeprazine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000443	0.00536	CbGeAlD
Methotrimeprazine—ADRA1A—brain—acquired immunodeficiency syndrome	0.000442	0.00534	CbGeAlD
Methotrimeprazine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.00044	0.00532	CbGeAlD
Methotrimeprazine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000439	0.00531	CbGeAlD
Methotrimeprazine—DRD2—brain—acquired immunodeficiency syndrome	0.000433	0.00523	CbGeAlD
Methotrimeprazine—HRH1—central nervous system—acquired immunodeficiency syndrome	0.00043	0.0052	CbGeAlD
Methotrimeprazine—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.00043	0.00519	CbGeAlD
Methotrimeprazine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000426	0.00515	CbGeAlD
Methotrimeprazine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000423	0.00511	CbGeAlD
Methotrimeprazine—ADRA2C—brain—acquired immunodeficiency syndrome	0.000421	0.00508	CbGeAlD
Methotrimeprazine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000419	0.00506	CbGeAlD
Methotrimeprazine—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000414	0.005	CbGeAlD
Methotrimeprazine—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000407	0.00491	CbGeAlD
Methotrimeprazine—HTR2A—lung—acquired immunodeficiency syndrome	0.000403	0.00487	CbGeAlD
Methotrimeprazine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000373	0.00451	CbGeAlD
Methotrimeprazine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.00036	0.00435	CbGeAlD
Methotrimeprazine—HRH1—brain—acquired immunodeficiency syndrome	0.000342	0.00413	CbGeAlD
Methotrimeprazine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.00034	0.00411	CbGeAlD
Methotrimeprazine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000336	0.00406	CbGeAlD
Methotrimeprazine—HRH1—lymph node—acquired immunodeficiency syndrome	0.00033	0.00399	CbGeAlD
Methotrimeprazine—CYP2E1—brain—acquired immunodeficiency syndrome	0.000328	0.00397	CbGeAlD
Methotrimeprazine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000328	0.00396	CbGeAlD
Methotrimeprazine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000324	0.00392	CbGeAlD
Methotrimeprazine—HTR2A—brain—acquired immunodeficiency syndrome	0.000285	0.00345	CbGeAlD
Methotrimeprazine—CYP2D6—brain—acquired immunodeficiency syndrome	0.00026	0.00314	CbGeAlD
Methotrimeprazine—Acepromazine—ALB—acquired immunodeficiency syndrome	9.83e-05	0.237	CrCbGaD
Methotrimeprazine—Thioproperazine—ALB—acquired immunodeficiency syndrome	9.61e-05	0.232	CrCbGaD
Methotrimeprazine—Pipotiazine—ALB—acquired immunodeficiency syndrome	9.45e-05	0.228	CrCbGaD
Methotrimeprazine—Clomipramine—ALB—acquired immunodeficiency syndrome	7.47e-05	0.18	CrCbGaD
Methotrimeprazine—Chlorpromazine—ALB—acquired immunodeficiency syndrome	5.12e-05	0.124	CrCbGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.23e-05	0.000303	CbGpPWpGaD
Methotrimeprazine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.23e-05	0.000303	CbGpPWpGaD
Methotrimeprazine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.22e-05	0.000302	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.21e-05	0.000301	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.21e-05	0.000301	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.18e-05	0.000299	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.18e-05	0.000298	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.16e-05	0.000297	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.16e-05	0.000297	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.16e-05	0.000297	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.16e-05	0.000297	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.14e-05	0.000295	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	3.12e-05	0.000293	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.000293	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	3.12e-05	0.000293	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.1e-05	0.000291	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.09e-05	0.000291	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.09e-05	0.00029	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.07e-05	0.000289	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.07e-05	0.000288	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.07e-05	0.000288	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.06e-05	0.000288	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.05e-05	0.000287	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.05e-05	0.000286	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.04e-05	0.000286	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.04e-05	0.000286	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.04e-05	0.000285	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.04e-05	0.000285	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.03e-05	0.000284	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.03e-05	0.000284	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.02e-05	0.000284	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.02e-05	0.000283	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.02e-05	0.000283	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.01e-05	0.000283	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.01e-05	0.000282	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3e-05	0.000282	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3e-05	0.000281	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.99e-05	0.000281	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.98e-05	0.00028	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.97e-05	0.000279	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.96e-05	0.000278	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.92e-05	0.000274	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.86e-05	0.000268	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.86e-05	0.000268	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.85e-05	0.000267	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.84e-05	0.000267	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.000264	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.8e-05	0.000263	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.8e-05	0.000263	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.79e-05	0.000262	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.79e-05	0.000262	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.79e-05	0.000262	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.78e-05	0.000261	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.77e-05	0.00026	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.76e-05	0.00026	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.76e-05	0.000259	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.75e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.75e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.75e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.74e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.74e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.74e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.74e-05	0.000257	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.71e-05	0.000255	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.71e-05	0.000255	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.71e-05	0.000254	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.67e-05	0.000251	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.67e-05	0.000251	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.67e-05	0.000251	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.67e-05	0.000251	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.63e-05	0.000247	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.63e-05	0.000247	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.000247	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.000247	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.59e-05	0.000244	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.58e-05	0.000242	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.56e-05	0.00024	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.55e-05	0.000239	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.53e-05	0.000238	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	2.53e-05	0.000238	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.53e-05	0.000237	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.52e-05	0.000237	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.52e-05	0.000237	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.51e-05	0.000236	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.51e-05	0.000236	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.49e-05	0.000234	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.48e-05	0.000233	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.48e-05	0.000233	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.44e-05	0.000229	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.44e-05	0.000229	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.42e-05	0.000227	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.42e-05	0.000227	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.41e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.41e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.41e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.4e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.39e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.38e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.38e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.38e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.38e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.37e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.37e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.37e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.37e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.37e-05	0.000222	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.36e-05	0.000222	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.36e-05	0.000222	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.36e-05	0.000221	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.34e-05	0.00022	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.34e-05	0.00022	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.34e-05	0.000219	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.34e-05	0.000219	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.33e-05	0.000219	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.33e-05	0.000219	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.31e-05	0.000217	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.31e-05	0.000217	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.26e-05	0.000212	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.2e-05	0.000206	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.17e-05	0.000204	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.15e-05	0.000202	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.14e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.12e-05	0.000199	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.12e-05	0.000199	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.11e-05	0.000198	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000196	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.06e-05	0.000193	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.03e-05	0.000191	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.03e-05	0.00019	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2e-05	0.000188	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.000188	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.97e-05	0.000185	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.000185	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.96e-05	0.000184	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.94e-05	0.000182	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.92e-05	0.00018	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.91e-05	0.00018	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.9e-05	0.000179	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.88e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.84e-05	0.000173	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.84e-05	0.000173	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.83e-05	0.000172	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.81e-05	0.00017	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.00017	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.00017	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.8e-05	0.000169	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.000169	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.8e-05	0.000169	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000168	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000168	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.79e-05	0.000168	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.78e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.77e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.77e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.76e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.76e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.75e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.75e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.75e-05	0.000164	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.75e-05	0.000164	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.74e-05	0.000164	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.73e-05	0.000162	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.72e-05	0.000162	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.000156	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.65e-05	0.000155	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.000153	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.000153	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.62e-05	0.000153	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.000153	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.6e-05	0.000151	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.6e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.6e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.6e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.59e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.59e-05	0.000149	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000149	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.57e-05	0.000147	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000147	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.56e-05	0.000147	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000146	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.49e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.45e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.41e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.4e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.39e-05	0.000131	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.38e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	1.38e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.27e-05	0.000119	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.27e-05	0.000119	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.26e-05	0.000119	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.25e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.25e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.25e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.25e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	1.16e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.13e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.12e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.06e-05	9.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.05e-05	9.88e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	9.77e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.03e-05	9.72e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.59e-06	9.01e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.54e-06	8.96e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.43e-06	8.86e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.41e-06	8.84e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.39e-06	8.82e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.38e-06	8.81e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.37e-06	8.8e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.35e-06	8.79e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.34e-06	8.77e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.31e-06	8.74e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.26e-06	8.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.24e-06	8.68e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.22e-06	8.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.19e-06	8.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.58e-06	8.06e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.54e-06	8.02e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.29e-06	7.79e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	8.25e-06	7.75e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.18e-06	7.68e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.83e-06	7.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.46e-06	7.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.37e-06	6.92e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.37e-06	6.92e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	6.99e-06	6.56e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.65e-06	6.25e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.39e-06	6e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.21e-06	5.83e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.11e-06	5.74e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.64e-06	5.29e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.55e-06	5.21e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.53e-06	5.2e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.52e-06	5.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.5e-06	5.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.44e-06	5.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.43e-06	5.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.05e-06	4.74e-05	CbGpPWpGaD
